CMTM6 and neoplasm: Chen et al. uncovered that higher expression of CMTM6 revealed a dismal outcome of HNSCC patients, and silencing CMTM6 could inhibit EMT and tumor stemness, suggesting it might be a favorable biomarker for HNSCC management [52].